Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Moleculin Biotech (MBRX) EBIT (2016 - 2025)

Moleculin Biotech's EBIT history spans 10 years, with the latest figure at -$7.5 million for Q4 2025.

  • Quarterly results put EBIT at -$7.5 million for Q4 2025, down 13.4% from a year ago — trailing twelve months through Dec 2025 was -$25.1 million (up 5.77% YoY), and the annual figure for FY2025 was -$25.1 million, up 5.77%.
  • EBIT for Q4 2025 was -$7.5 million at Moleculin Biotech, down from -$5.9 million in the prior quarter.
  • In the past five years, EBIT ranged from a high of -$5.2 million in Q4 2021 to a low of -$9.1 million in Q3 2022.
  • The 5-year median for EBIT is -$6.5 million (2023), against an average of -$6.7 million.
  • The sharpest move saw EBIT tumbled 48.93% in 2021, then surged 34.53% in 2023.
  • Year by year, EBIT stood at -$5.2 million in 2021, then plummeted by 35.41% to -$7.0 million in 2022, then decreased by 26.55% to -$8.9 million in 2023, then grew by 25.52% to -$6.6 million in 2024, then dropped by 13.4% to -$7.5 million in 2025.
  • According to Business Quant data, EBIT over the past three periods came in at -$7.5 million, -$5.9 million, and -$5.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.